Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Alabama for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Alabama only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Alabama (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Ehab El-bahesh (NPI 1467689505)

Field	Value
Entity Type	Individual
Organization	Ehab El-bahesh
Address	3601 Cci Dr Nw
City	Huntsville
State	AL
ZIP	35805
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	June 16, 2009

Payer Source	Total Paid
Medicare	$1.7M
Medicaid	$0

Key Findings

This provider’s Medicare footprint is the dominant payer relationship: lifetime Medicare revenue is $1.7M while Medicaid billing is listed as none (no Medicaid billing on file), making the practice effectively single-payer (Medicare) in the dataset. That concentration means analyses of utilization, quality, and contracting should be Medicare-first.

Revenue is highly concentrated in a small set of drug and biologic codes: the top 3 Medicare codes account for 62.5% of total Medicare revenue, led by J9173 ($492.9K, 30.4%), J9271 ($318.2K, 19.6%), and Q5127 ($200.9K, 12.4%). This concentration indicates most Medicare income is driven by a few high-cost injectable therapies rather than diffuse office-based fees.

The code mix is consistent with an outpatient hematology/oncology infusion practice that administers checkpoint inhibitors and supportive biologics: high-revenue drug codes J9173 (durvalumab) and J9271 (pembrolizumab), plus biosimilar pegfilgrastim Q5127 and multiple chemotherapy administration codes (96413, 96365, G0498) appear prominently. Office E/M codes (99214, 99213) and lab panels (80053, 85025, 36415) further support a clinic workflow combining infusion care with on-site monitoring and management.

Competitive standing is mixed across specific drugs: J9173 ranks #7 of 53 (88th percentile; typical, unremarkable volume for this code) and Q5127 ranks #5 of 30 (86th percentile; typical, unremarkable volume for this code), indicating comparatively high national placement for durvalumab and this pegfilgrastim biosimilar within the sampled provider pools. By contrast, J9271 ranks #1485 of 1841 (19th percentile; typical, unremarkable volume for this code), showing relatively low national placement for pembrolizumab usage despite it being the second-largest revenue source for this provider.

Several visit and infusion-related codes are notable for above-typical national volume: 99214 generated $76.9K from 874 claims and ranks #15886 of 479517 (97th percentile; notably above typical national volume for this code), while 96375 generated $9.3K and ranks #233 of 5191 (96th percentile; notably above typical national volume for this code). These high percentiles for E/M and add-on infusion services reinforce that the clinic delivers substantial face-to-face management and sequential IV therapy beyond just dispensing drugs.

Certain ancillary services and labs show especially high relative volumes, consistent with on-site specimen collection and testing: 80053 had 1.8K claims and $18.4K revenue and ranks #694 of 26416 (97th percentile; typical, unremarkable volume for this code), and 36415 had 1.8K claims and $14.6K revenue and ranks #1078 of 86467 (99th percentile; typical, unremarkable volume for this code). High percentile ranks on routine lab and phlebotomy codes suggest an integrated clinic model that performs its own monitoring rather than outsourcing those services.

Certain specialty add-on and supportive drug codes are also outliers toward the high end of national samples: J1454 produced $47.8K and ranks #30 of 422 (93th percentile; notably above typical national volume for this code), while 96375 and other add-on infusion codes similarly show "notably above typical" national volume. These patterns point to a meaningful level of complex supportive care (e.g., antiemetic combos and sequential infusions) in the practice’s case mix.

The provider has an established NPI history, enumerated on 2009-06-16 (~17 years ago), which—combined with $1.7M in Medicare lifetime revenue—suggests a stable, mid-sized Medicare-facing oncology practice. The absence of Medicaid billing on file may reflect deliberate payer participation choices or billing under alternate/group NPIs, and is material for payer contracting and network participation assessments given the effectively Medicare-only footprint in this record.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

87 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9173	Injection, durvalumab, 10 mg	7,950	$60	$492.9K
J9271	Injection, pembrolizumab, 1 mg	7,400	$40	$318.2K
Q5127	Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg	740	$270	$200.9K
J0897	Injection, denosumab, 1 mg	5,400	$20	$97.2K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	870	$90	$76.9K
J1437	Injection, ferric derisomaltose, 10 mg	4,300	$20	$73.1K
J0642	Injection, levoleucovorin (khapzory), 0.5 mg	67,050	$1	$67K
J1454	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg	140	$340	$47.8K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	500	$90	$45.7K
Q5108	Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg	400	$100	$39.6K

Showing 1–10 of 87

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 87 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Alabama Distribution

Ehab El-bahesh — 5 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Alabama

Full comparison — all codes billed, vs. state median

87 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	30	30	19,900	$40	$827.2K
J9173	2	10	8,340	$60	$517.6K
Q5127	4	20	590	$270	$165.7K
J0897	66	200	3,120	$20	$97.7K
J0642	4	10	81,310	$1	$81.3K
J1437	11	40	3,000	$20	$59.1K
Q5108	3	10	370	$100	$38.1K
J1454	5	20	90	$340	$33.7K
J0881	21	30	7,720	$1	$24.1K
96413	19	150	150	$90	$20.2K

Showing 1–10 of 87

Related Providers

Other providers that share a Tax Identification Number (TIN) with Ehab El-bahesh, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
John Waples	AL	Medical Oncology Physician	$9.6M	$0
Marshall Schreeder	AL	Medical Oncology Physician	$3.5M	$0
Heather Brody	AL	Hematology & Oncology Physician	$3.1M	$0
Jorge Diaz	AL	Hematology & Oncology Physician	$2.6M	$0
Naveen Lobo	AL	Medical Oncology Physician	$2.4M	$0
Ali Hachem	AL	Hematology & Oncology Physician	$2.3M	$0
Daniel Schreeder	AL	Hematology & Oncology Physician	$2.3M	$0
Robert Conry	AL	Hematology & Oncology Physician	$2.1M	$0
Lakshmikanth Katragadda	AL	Hematology & Oncology Physician	$2.1M	$0
Oncology Specialties, P.C.	AL	Hematology & Oncology Physician	$0	$2M

Nearby Providers

Other providers in the same ZIP code as Ehab El-bahesh, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Huntsville Emergency Medical Services, Inc.	AL	Land Ambulance	$5.6M	$6M
Madison Core Laboratories, LLC	AL	Clinical Medical Laboratory	$1.5M	$4M
Hc Healthcare, LLC	AL	Community Based Hospice Care Agency	$0	$4.8M
The Village Medical Clinic	AL	Specialist	$0	$2M
Pathology Associates, P.C.	AL	Anatomic Pathology & Clinical Pathology Physician	$0	$1.7M
Rehabilitation & Neurological Services LLC	AL	Specialist	$0	$1.3M
Philip Mcgee	AL	Hematology & Oncology Physician	$1.2M	$0
John Nicholson	AL	Hematology & Oncology Physician	$1.2M	$0
Elizabeth Falkenberg	AL	Radiation Oncology Physician	$1.1M	$0
Diego Bedoya	AL	Hematology & Oncology Physician	$1.1M	$0

Ehab El-bahesh — Billing Profile & Reimbursement Data

Sign up for Ehab El-bahesh — Billing Profile & Reimbursement Data policy alerts

Ehab El-bahesh — Billing Profile & Reimbursement Data

Sign up for Ehab El-bahesh — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References